Autologous T cells are genetically engineered to express a T-cell receptor that recognizes KRAS G12V or G12D neoantigen peptides presented on HLA-A*11, C*01:02, or C*08:02. Following lymphodepletion and infusion, these TCR-T cells engage peptide–HLA complexes on KRAS-mutant tumor cells and mediate MHC-restricted cytotoxic killing via TCR signaling with perforin/granzyme release and cytokine production.